Abstract:Introduction Natural Killer (NK) cells hold the potential to shift cell therapy from a complex autologous option to a universal off-the-shelf one. Although NK cells have demonstrated efficacy and safety in the treatment of leukemia, the limited efficacy of NK cell-based immunotherapies against solid tumors still represents a major hurdle. In the immunosuppressive tumor microenvironment (TME), inhibitory interactions between cancer and immune cells impair antitumoral immunity. KLRC1 gene encodes the NK cell inhibitory receptor NKG2A, which is a potent NK cell immune checkpoint. NKG2A specifically binds HLA-E, a non-classical HLA class I molecule frequently overexpressed in tumors, leading to the transmission of inhibitory signals that strongly impair NK cell function. Methods To restore NK cell cytotoxicity against HLA-E + tumors, we have targeted the NKG2A/HLA-E immune checkpoint by using a CRISPR-mediated KLRC1 gene editing. Results KLRC1 knockout resulted in a reduction of 81% of NKG2A + cell frequency in ex vivo expanded human NK cells post-cell sorting. In vitro , the overexpression of HLA-E by tumor cells significantly inhibited wild-type (WT) NK cell cytotoxicity with p -values ranging from 0.0071 to 0.0473 depending on tumor cell lines. In contrast, KLRC1 KO NK cells exhibited significantly higher cytotoxicity when compared to WT NK cells against four different HLA-E + solid tumor cell lines, with p -values ranging from<0.0001 to 0.0154. Interestingly, a proportion of 43.5% to 60.2% of NKG2A − NK cells within the edited NK cell population was sufficient to reverse at its maximum the HLA-E-mediated inhibition of NK cell cytotoxicity. The expression of the activating receptor NKG2C was increased in KLRC1 KO NK cells and contributed to the improved NK cell cytotoxicity against HLA-E + tumors. In vivo , the adoptive transfer of human KLRC1 KO NK cells significantly delayed tumor progression and increased survival in a xenogeneic mouse model of HLA-E + metastatic breast cancer, as compared to WT NK cells ( p = 0.0015). Conclusions Our results demonstrate that KLRC1 knockout is an effective strategy to improve NK cell antitumor activity against HLA-E + tumors and could be applied in the development of NK cell therapy for solid tumors.

P1368: NKG2A DELETION IN HUMAN NATURAL KILLER CELLS ENHANCES ANTI-TUMOR RESPONSES AND PROMOTES TUMOR INFILTRATION

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody

Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy

Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer

KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors

Possible Association Of Decreased Nkg2d Expression Levels And Suppression Of The Activity Of Natural Killer Cells In Patients With Colorectal Cancer

Human NK cells: surface receptors, inhibitory checkpoints, and translational applications

Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?

Attribution Of Nkg2dl To The Inhibition Of Early Stage Allogeneic Tumors In Mice

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy

The NKG2A immune checkpoint — a new direction in cancer immunotherapy

Natural killer cells in cancer immunotherapy

Updating targets for natural killer/T-cell lymphoma immunotherapy

Developing enhanced immunotherapy using NKG2A knockout human pluripotent stem cell-derived NK cells

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells

NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity

Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer

NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells

Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line